[Form 3] INmune Bio Inc. Common stock Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

INmune Bio (INMB) Form 3: Cory Randall Ellspermann, listed as a director and Interim CFO, reported beneficial ownership of stock options totaling 245,000 shares. The filing lists five option grants exercisable on dates between 11/24/2029 and 12/04/2034 with exercise prices from $3.91 to $21.06. One option is noted as fully vested and other grants include stated vesting schedules.

Positive

• 245,000 stock options disclosed across five grants, providing clear transparency of insider holdings
• Reporting person identified as Interim CFO and director, aligning executive role with disclosed equity compensation

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine Section 16 filing disclosing an officer/director's option holdings and vesting schedule; no unexpected departures or transactions.

The Form 3 documents initial beneficial ownership and shows alignment of an executive with equity compensation in the company. It confirms the reporting person serves as Interim CFO and a director and discloses five option awards with specific exercise prices and exercisable dates. The filing does not disclose cash transactions, share sales, or changes to board composition beyond the listed roles.

Securities Analyst

TL;DR: Non-material, routine disclosure of equity awards by a company insider; useful for recordkeeping but not market-moving on its own.

The table quantifies five option grants totaling 245,000 underlying shares and provides exercise prices and future exercisability dates. One grant is stated as fully vested while others follow monthly vesting or specific future vest dates. There are no derivative exercises, purchases, or dispositions reported in this filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ellspermann Cory Randall

(Last) (First) (Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON FL 33432

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2025

3. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	(1)	11/24/2029	Common Stock	75,000	$3.91	D
Stock Options	(1)	07/22/2031	Common Stock	40,000	$21.06	D
Stock Options	(1)	03/20/2032	Common Stock	30,000	$7.92	D
Stock Options	(2)	05/13/2034	Common Stock	30,000	$9.92	D
Stock Options	(3)	12/04/2034	Common Stock	70,000	$5.05	D

Explanation of Responses:

1. The option is fully vested.

2. The option vested or vests as to one-forty-eighth (1/48) of the total award monthly, with the first tranche vesting on June 14, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the Reporting Person's continued service with the Issuer on each vesting date.

3. The option vests and becomes exercisable on December 5, 2026, subject to the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ CORY RANDALL ELLSPERMANN	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cory Randall Ellspermann disclose on the INMB Form 3?

The filing discloses beneficial ownership of 245,000 stock options across five grants with exercise prices from $3.91 to $21.06 and exercisable dates between 11/24/2029 and 12/04/2034.

What roles does the reporting person hold at INmune Bio (INMB)?

The Form 3 lists Cory Randall Ellspermann as a Director and the company's Interim CFO.

Are any of the options fully vested according to the filing?

Yes. The filing includes an explanation stating one option is fully vested.

When was the event requiring this Form 3 reported?

The date of the event requiring the statement is listed as 08/04/2025.

Do the disclosed awards include vesting schedules?

Yes. The filing notes monthly vesting for one award (one-forty-eighth per month beginning 06/14/2024) and specific vest dates for other grants.